HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $27
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Tyra Biosciences (NASDAQ:TYRA) with a Buy and lowers the price target from $29 to $27.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Tyra Biosciences (NASDAQ:TYRA) with a Buy and lowers the price target from $29 to $27.